These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26832357)

  • 1. Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening.
    Omabe M; Omabe KN; Clement FA; Omabe GM
    Endocr Metab Immune Disord Drug Targets; 2016; 16(1):61-71. PubMed ID: 26832357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reproductive phenotype in polycystic ovary syndrome.
    Chang RJ
    Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):688-95. PubMed ID: 17893687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-Mullerian hormone in the major phenotypes of polycystic ovary syndrome].
    Parahuleva N; Pehlivanov B; Orbecova M; Uchikova E; Ivancheva H
    Akush Ginekol (Sofiia); 2014; 53(5):22-7. PubMed ID: 25558667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
    Sung YA; Oh JY; Chung H; Lee H
    Fertil Steril; 2014 Mar; 101(3):840-5. PubMed ID: 24424368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Tosi F; Negri C; Perrone F; Dorizzi R; Castello R; Bonora E; Moghetti P
    J Clin Endocrinol Metab; 2012 May; 97(5):1712-9. PubMed ID: 22419715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
    Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
    Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome in adolescent girls.
    Baldauff NH; Witchel SF
    Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):56-66. PubMed ID: 27906711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.
    Moran L; Teede H
    Hum Reprod Update; 2009; 15(4):477-88. PubMed ID: 19279045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome.
    Pergialiotis V; Trakakis E; Chrelias C; Papantoniou N; Hatziagelaki E
    Horm Mol Biol Clin Investig; 2018 Mar; 34(3):. PubMed ID: 29596052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.
    Carmina E; Orio F; Palomba S; Longo RA; Lombardi G; Lobo RA
    Fertil Steril; 2005 Aug; 84(2):413-9. PubMed ID: 16084883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
    Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of polycystic ovary syndrome: involvement of genetic and environmental factors.
    Franks S; McCarthy MI; Hardy K
    Int J Androl; 2006 Feb; 29(1):278-85; discussion 286-90. PubMed ID: 16390494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adropin in women with polycystic ovary syndrome.
    Kuliczkowska-Płaksej J; Mierzwicka A; Jończyk M; Stachowska B; Urbanovych A; Bolanowski M
    Endokrynol Pol; 2019; 70(2):151-156. PubMed ID: 30480749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population.
    Zhang HY; Zhu FF; Xiong J; Shi XB; Fu SX
    BJOG; 2009 Nov; 116(12):1633-9. PubMed ID: 19781047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.